Turkish Journal of Gastroenterology
Original Article

Pentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?

1.

Department of Infectious Diseases and Clinical Microbiology, Fırat University School of Medicine, Elazığ, Turkey

2.

Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University School of Medicine, Hatay, Turkey

3.

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Fırat University, Elazığ, Turkey

4.

Department of Pathology, Sütçü İmam University School of Medicine, Kahramanmaraş, Turkey

5.

Department of Biochemistry, Fırat University School of Medicine, Elazığ, Turkey

Turk J Gastroenterol 2019; 1: -
DOI: 10.5152/tjg.2020.19378
Read: 196 Published: 30 April 2020

Background/Aims: PTX-3 is an important marker that plays a role in suppressing inflammation and tissue repair. The aim of this study is to investigate the diagnostic and prognostic characteristics of PTX-3 in CHB patients and the relationship between PTX-3 levels and fibrosis.

Materials and Methods: A total of 52 CHB patients and 40 healthy subjects were included in the study. All of the CHB patients underwent liver biopsy and were then scored using a Ishak histologic scoring system. Blood samples were collected to evaluate the PTX-3 levels.

Results: Of the subjects who participated in the study, 53% were female. PTX-3 levels were determined as 5.63ng/mL in the control group, and as 0.88ng/mL in the CHB patient group. PTX-3 levels were found to be 1.19ng/mL in stage 1, 0.89ng/mL in stage 2, 0.68ng/mL in stage 3 and 0.55ng/mL in stage 4. Of the CHB patients, 44.2% had significant fibrosis, while 55.7% were identified as not having significant fibrosis. PTX-3 values were 0.64 and 1.0ng/mL in patients with and without significant fibrosis, respectively. The cut-off value for PTX-3 in predicting the absence of significant fibrosis was estimated as 0.9ng/mL.

Conclusion: CHB patients were found to have lower serum PTX-3 levels compared to the control group, and these levels decreased even further as the fibrosis stage progressed in these patients. In addition, the significant decrease in PTX-3 levels in patients with stage 1 fibrosis compared to the control group shows that PTX-3 can be used as a non-invasive marker for the early detection of fibrosis (p<0.001).

EISSN 2148-5607